Comparison of Cisplatin plus Vindesine with Cisplatin plus Mitomycin C for Treatment of Advanced Non-Small-Cell Lung Cancer
作者:
Eiji Shimizu,
Takeshi Ogura,
Saburo Sone,
Tadashi Nakayama,
Hiroyuki Doi,
Yoshihiro Takishita,
Hiroyasu Bando,
Masaki Kobayashi,
Kouichi Kimura,
Haruo Sasaki,
Takaki Hashimoto,
Yuhji Higuchi,
Ichiro Kawase,
期刊:
Oncology
(Karger Available online 1993)
卷期:
Volume 50,
issue 1
页码: 5-9
ISSN:0030-2414
年代: 1993
DOI:10.1159/000227138
出版商: S. Karger AG
关键词: Non-small-cell lung cancer;Chemotherapy;Randomized trial;Cisplatin;Mitomycin C;Vindesine
数据来源: Karger
摘要:
Seventy-six patients with advanced non-small-cell lung cancer were randomly allocated to two groups and treated with cisplatin (CDDP; 80 mg/m2 on day 1) plus either vindesine (VDS; 3 mg/m2 on days 1 and 8) or mitomycin C (MMC; 8 mg/m2 on days 1 and 8) every 3-4 weeks. The objective response rates were 26% (10/38) for CDDP plus VDS and 32% (11/34) for CDDP plus MMC; the corresponding response rates in patients with adenocarcinoma were 7% (1/14) and 43% (6/14), respectively. The median survival times ofpatients treated with CDDP plus VDS and CDDP plus MMC were 33 and 30 weeks, respectively, the difference in survival times in the two groups not being significant. There was no significant difference in toxic effects in the two groups except that alopecia and leukopenia were more frequent in patients treated with CDDP plus VDS.
点击下载:
PDF
(2251KB)
返 回